Advertisement

International Ophthalmology

, Volume 38, Issue 6, pp 2593–2597 | Cite as

Efficacy of locally produced Latanoprost in the control of intraocular pressure in patients with primary open-angle glaucoma

  • Pir Salim MaharEmail author
  • Nadeem H. Butt
  • Syed Imtiaz Ali
Original Paper
  • 107 Downloads

Abstract

Purpose

To determine the efficacy of locally produced Latanoprost in reducing the intraocular pressure (IOP) in patients with Primary open-angle glaucoma (POAG).

Design

Open-label, non-comparative, observational case study with non-probability purposive sampling.

Methods

A total of 48 patients (94 eyes) of either gender were recruited from glaucoma clinic with the diagnosis of POAG, having IOP of more than 21 mmHg. Patients were commenced on locally produced Latanoprost (Vislat 0.005%). IOP was subsequently measured at 4 weeks and 12 weeks, respectively. The primary end point was reduction in IOP at 12 weeks after the initiation of treatment.

Results

A total of 48 patients (94 eyes) were recruited from glaucoma clinic. The average IOP of our patients at baseline was 28.6 ± 8.1 mmHg, decreasing to 21.3 ± 10.6 mmHg at 4 weeks, indicating a drop of 19.1% (P < 0.001). IOP further decreased to 20.3 ± 8.7 mmHg after 3 months of treatment indicating a decrease of 23.3% (P < 0.001). A decrease in IOP occurred in 51 eyes (71.8%) at 4 weeks after treatment, improving to 54 eyes (76%) at 3-month follow-up. Twenty eyes (28.1%) did not show any change in IOP at 4 weeks. However, after 3-month follow-up only 17 eyes (23.9%) did not reveal any change in IOP.

Conclusion

Our results showed a decrease in IOP of 19.1% after 4 weeks, increasing to 23.3% at 12 weeks in cohort of 37 patients (72 eyes) treated with locally produced Latanoprost (Vislat 0.005%).

Keywords

Latanoprost Intraocular pressure Primary open-angle glaucoma 

Notes

Acknowledgements

We are thankful to Dr. Mujahid Inam, Dr. Nasir Memon and Dr. Shahid Rashidi for recruiting and enrolling the patients, Muhammad Faisal Fahim for statistical analysis and Azfar Ali for typing the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Ocklind A (1998) Effect of Latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 67:179–191CrossRefGoogle Scholar
  2. 2.
    Kim JW, Lindsey JD, Wang N et al (2001) Increased human sclera permeability with prostaglandin exposure. Invest Ophthalmol Vis Sci 42:1514–1521PubMedGoogle Scholar
  3. 3.
    Larsson LI (2001) Intraocular pressure over 24 hours after single-dose administration of Latanoprost 0.005% in healthy volunteers. A randomized, double-masked, placebo controlled, cross-over single center study. Acta Ophthalmol Scand 79:567–571CrossRefGoogle Scholar
  4. 4.
    Camras CB (1996) Comparison of Latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked, multicenter trial in the United States. The United States Latanoprost Study Group. Ophthalmology 103:138–147CrossRefGoogle Scholar
  5. 5.
    Aml A, Stjernschantz J (1995) Effects on intraocular pressure and side effects of 0.005% Latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 102:1743–1752CrossRefGoogle Scholar
  6. 6.
    Watson P, Stjernschantz J (1996) A six-month randomized, double-masked study comparing Latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology 103:126–137CrossRefGoogle Scholar
  7. 7.
    Hedman K, Watson P, Alm A (2002) The effect of Latanoprost on Intraocular pressure during 2 years of treatment. Survey Ophthalmol 47:65–75CrossRefGoogle Scholar
  8. 8.
    Allauire C, Dietrich A, Allmeir H, Grundmane I, Mazur-Piotrowska G, Kahle G (2012) Latanoprost 0.005%, test formulation is as effective as Xalatan in patients with ocular hypertension and primary open angle glaucoma. Eur J Ophthalmol 22(1):19–27CrossRefGoogle Scholar
  9. 9.
    Golan S, Rosenfeld E, Shemesh G, Kurtz S (2015) Original and generic Latanoprost for the treatment of glaucoma and ocular hypertension are really the same? Clin Exp Pharmacol Physiol 42(2):220–224CrossRefGoogle Scholar
  10. 10.
    Digiuni M, Manni G, Vetrugno M, Uva M, Milano G, Orzalesi N et al (2013) An evaluation of therapeutic non-inferiority of 0.005% Latanoprost ophthalmic solution and Xalatan in patients with glaucoma or ocular hypertension. J Glaucoma 22(9):707–712CrossRefGoogle Scholar
  11. 11.
    Hashemi M, Miraftabi A, Nilforoushan N, Ghasemi Falaranjani K, Pakdel F, Soudi R et al (2012) Comparison of the efficacy and tolerability of Xalatan and Xalabiost (Generic Latanoprost) in adults with open angle glaucoma and ocular hypertension. A two-center, randomized crossover trial. Iran J Ophthalmol 24(3):11–18Google Scholar
  12. 12.
    Narayanaswamy A, Neog A, Baskaran M, Gewge R, Lingham V, Desai C, Rajadhyaksha V (2007) A randomized crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with gerneric Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J Ophthalmol 55(2):127–131CrossRefGoogle Scholar
  13. 13.
    Scherer WJ (2004) A retrospective review of non-responders to Latanoprost. J Ocular Pharmacol Ther 18(3):287–291CrossRefGoogle Scholar
  14. 14.
    Ikeda Y, Mori K, Ishibashi T, Naruse S, Nakajima N, Kinoshita S (2006) Latanoprost nonresponders with open-angle glaucoma in the Japanese population. Jap J Ophthalmol 50(2):153–157CrossRefGoogle Scholar
  15. 15.
    Rossetti L, Gandolfi S, Traverso C, Montanari P, Uva M, Manni G et al (2006) An evaluation of the rate of non-responders to Latanoprost therapy. J Glaucoma 15(3):238–243CrossRefGoogle Scholar
  16. 16.
    Stein JD, Shekhawat N, Talwar N, Balkrishnan R (2015) Importance of the introduction of generic Latanoprost on glaucoma medication adherence. Ophthalmol 122(4):738747CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2017

Authors and Affiliations

  • Pir Salim Mahar
    • 1
    • 2
    Email author
  • Nadeem H. Butt
    • 3
  • Syed Imtiaz Ali
    • 4
  1. 1.Isra Postgraduate Institute of OphthalmologyAl-Ibrahim Eye HospitalMalir, KarachiPakistan
  2. 2.Aga Khan University HospitalKarachiPakistan
  3. 3.Allama Iqbal Medical CollegeLahorePakistan
  4. 4.Al-Nafees Medical CollegeIslamabadPakistan

Personalised recommendations